Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Senate bill would repeal competitive bidding demo

This article was originally published in The Gray Sheet

Executive Summary

A Senate bill (S. 2099) to repeal CMS' competitive bidding demonstration project for clinical laboratories is introduced Sept. 26 and applauded by the American Clinical Laboratory Association. ACLA is lobbying Sens. Max Baucus (D-Mont.) and Charles Grassley (R-Iowa) to attach language in the bill to a separate package of Medicare reform provisions that Congress is expected to consider this year. Introduced by Sens. Ken Salazar (D-Col.), Pat Roberts (R-Kan.) and Maria Cantwell (D-Wash.), the bill mirrors similar legislation in the House (H.R. 3453) to stop CMS from carrying out the demonstration project to assess the cost-saving potential of replacing Medicare's lab fee schedule with prices based on the lowest bids from labs ("1The Gray Sheet" Aug. 13, 2007, p. 8)

You may also be interested in...

Bill Would Stop Competitive Bidding Demonstration For Laboratory Services

A bill introduced in the House Aug. 4 would cancel a Medicare clinical laboratory services competitive bidding demonstration project before it begins

QUOTED. 3 April 2020. Minetta Liu.

Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.

Colorectal, Bladder Cancer Therapies Are Top Prospects For April US FDA Approvals

Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts